RPG LifeScience.

Has RPG LifeScience. declared dividend?

RPG Life Sciences Ltd has declared a 200% dividend, amounting to ₹16 per share, with an ex-date of June 28, 2024. The company has shown significant total returns over various periods, particularly in the long term, despite a recent short-term decline.

RPG Life Sciences Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 16<BR>- Ex-date: 28 Jun 24<BR><BR>Dividend Yield: 0.74%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -2.98%, with a dividend return of 0%, resulting in a total return of -2.98%.<BR><BR>Over the past year, the price return was 47.74%, the dividend return was 1.03%, leading to a total return of 48.77%.<BR><BR>In the 2-year period, the price return was 168.65%, the dividend return was 3.07%, culminating in a total return of 171.72%.<BR><BR>For the 3-year period, the price return was 316.33%, with a dividend return of 7.27%, resulting in a total return of 323.6%.<BR><BR>In the last 4 years, the price return was 388.09%, the dividend return was 9.96%, giving a total return of 398.05%.<BR><BR>Over the past 5 years, the price return was 661.83%, with a dividend return of 16.67%, leading to a total return of 678.5%.<BR><BR>Overall, RPG Life Sciences Ltd has declared a substantial dividend, and the total returns over various periods reflect significant growth, particularly in the longer term, despite a recent decline in the short-term price return.

Who are the peers of the RPG LifeScience.?

RPG LifeScience's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Morepen Labs, Orchid Pharma, Advanced Enzyme, and Guj. Themis Bio. Key performance indicators show excellent management risk and growth for Sun Pharma, Cipla, and Dr Reddy's Labs, while RPG LifeScience has below-average growth and a 1-year return of 53.50%.

Peers: RPG LifeScience's peers include Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Morepen Labs., Orchid Pharma, Advanced Enzyme, Guj. Themis Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience, Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Advanced Enzyme, and Guj. Themis Bio, while Average management risk is found at Morepen Labs. and Below Average management risk is noted at Orchid Pharma and Panacea Biotec. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at RPG LifeScience, Torrent Pharma, Orchid Pharma, and Panacea Biotec. The Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Morepen Labs., Advanced Enzyme, and Guj. Themis Bio, while Good is noted for Torrent Pharma, and Below Average is found at Orchid Pharma and Panacea Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 269.46%, while Orchid Pharma has the lowest at -31.48%. RPG LifeScience's own 1-year return is 53.50%, which is significantly higher than Orchid Pharma's but lower than Panacea Biotec's. Additionally, the peers with negative six-month returns include Orchid Pharma, Advanced Enzyme, and Guj. Themis Bio.

Who are in the management team of RPG LifeScience.?

As of March 2018, the management team of RPG LifeScience includes Chairman H V Goenka, Managing Director C T Renganathan, and Company Secretary Rajesh Shirambekar, along with several Non-Executive Independent Directors and a Non-Executive Director, Sachin Nandgaonkar. The team features a mix of executive and non-executive roles.

As of March 2018, the management team of RPG LifeScience includes the following individuals:<BR><BR>1. H V Goenka - Chairman<BR>2. C T Renganathan - Managing Director<BR>3. Rajesh Shirambekar - Company Secretary<BR><BR>Additionally, the board features several Non-Executive Independent Directors:<BR>- C L Jain<BR>- Lalit S Kanodia<BR>- Mahesh S Gupta<BR>- Manoj K Maheshwari<BR>- Narendra Ambwani<BR>- Zahabiya Khorakiwala<BR>- Yugal Sikri<BR><BR>There is also a Non-Executive Director, Sachin Nandgaonkar. <BR><BR>As of March 2018, RPG LifeScience has a diverse management team with a mix of executive and non-executive roles.

What does RPG LifeScience. do?

RPG Life Sciences Ltd manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients. As of March 2025, it reported net sales of ₹1,431 Cr and a net profit of ₹1,174 Cr, with a market cap of ₹4,251 Cr.

Overview:<BR>RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap company.<BR><BR>History:<BR>RPG Life Sciences Limited, originally incorporated as Searle India Limited in 1968, underwent a status change when GD Searle withdrew from India in 1993, leading to the RPG Group acquiring its holdings. The company was later incorporated under its current name on March 29, 2007. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,431 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,174 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 4,251 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 46.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.94% <BR>Debt Equity: -0.50 <BR>Return on Equity: 17.95% <BR>Price to Book: 8.00 <BR><BR>Contact Details:<BR>Address: RPG House, 463 Dr Annie Besant Road Worli Mumbai Maharashtra : 400030 <BR>Tel: 91-022-24981650 <BR>Email: info@rpglifesciences.com <BR>Website: http://www.rpglifesciences.com

Who are the top shareholders of the RPG LifeScience.?

The top shareholders of RPG LifeScience include Nucleus Life Trust with 53.94%, Authum Investment And Infrastructure Limited at 2.02%, and individual investors holding 15.33%. Additionally, mutual funds hold 3.53%, and 46 foreign institutional investors have a combined stake of 1.45%, with no pledged promoter holdings reported.

The top shareholders of RPG LifeScience include the promoters, with Nucleus Life Trust, managed by Mr. Harsh Vardhan Goenka as a trustee, holding the largest stake at 53.94%. Other significant shareholders include Authum Investment And Infrastructure Limited, which holds 2.02%, and individual investors collectively owning 15.33%. Additionally, the company has mutual funds represented by six schemes, holding 3.53%, and 46 foreign institutional investors (FIIs) with a combined holding of 1.45%. There are no pledged promoter holdings reported.

How big is RPG LifeScience.?

As of 24th July, RPG Life Sciences Ltd has a market capitalization of 4,142.00 Cr, classifying it as a Small Cap company, with recent Net Sales of 653.43 Cr and a Net Profit of 183.24 Cr. Specific values for Shareholder's Funds and Total Assets are not available.

As of 24th July, RPG Life Sciences Ltd has a market capitalization of 4,142.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, RPG Life Sciences reported Net Sales of 653.43 Cr and a Net Profit of 183.24 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period. However, specific values for Shareholder's Funds and Total Assets are not available.

How has been the historical performance of RPG LifeScience.?

RPG LifeScience has shown consistent growth in net sales and profits, with net sales rising from 330.16 Cr in March 2019 to 653.43 Cr in March 2025, and profit after tax increasing from 10.81 Cr to 183.24 Cr in the same period, reflecting strong financial performance and enhanced shareholder value.

Answer:<BR>The historical performance of RPG LifeScience shows a consistent growth trajectory in net sales and profits over the years. <BR><BR>Breakdown:<BR>RPG LifeScience's net sales have increased from 330.16 Cr in March 2019 to 653.43 Cr in March 2025, reflecting a strong upward trend. The total operating income has followed the same pattern, rising from 330.16 Cr in March 2019 to 653.43 Cr in March 2025. The company's operating profit, excluding other income, has also seen significant growth, climbing from 33.56 Cr in March 2019 to 159.65 Cr in March 2025. This is complemented by an increase in profit before tax, which surged from 15.05 Cr in March 2019 to 232.88 Cr in March 2025. The profit after tax has similarly escalated from 10.81 Cr in March 2019 to 183.24 Cr in March 2025, indicating improved profitability. The earnings per share have dramatically increased from 6.54 in March 2019 to 110.8 in March 2025, showcasing enhanced shareholder value. Overall, RPG LifeScience has demonstrated robust financial performance with increasing revenues and profits over the years.

Is RPG LifeScience. overvalued or undervalued?

As of November 7, 2025, RPG LifeScience is fairly valued with a PE Ratio of 35.54, strong operational efficiency indicated by a ROCE of 46.94% and ROE of 21.01%, and has outperformed the Sensex over the last three and five years, making it an attractive investment compared to its peers.

As of 7 November 2025, the valuation grade for RPG LifeScience has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 35.54, an EV to EBITDA of 24.78, and a PEG Ratio of 0.84, indicating a relatively attractive growth potential compared to its price.<BR><BR>In comparison to its peers, RPG LifeScience's PE Ratio is slightly higher than Sun Pharma's 35.17 but significantly lower than Divi's Lab's 71.11, which is categorized as very expensive. Additionally, while Cipla is rated as attractive with a PE of 22.33, RPG LifeScience's strong ROCE of 46.94% and ROE of 21.01% suggest robust operational efficiency. Notably, RPG LifeScience has outperformed the Sensex over the last three and five years, with returns of 174.55% and 559.32%, respectively, reinforcing its competitive position in the market.

Is RPG LifeScience. technically bullish or bearish?

As of December 3, 2025, the technical trend for RPG LifeScience has shifted to mildly bearish, influenced by bearish signals from the MACD, KST, and Bollinger Bands, despite a mildly bullish daily moving average.

As of 3 December 2025, the technical trend has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by several key indicators. The MACD is bearish on the weekly chart and mildly bearish on the monthly chart, while the KST also shows bearish signals on both time frames. The Dow Theory indicates a mildly bearish stance for both weekly and monthly periods. Although the daily moving averages show a mildly bullish trend, the overall sentiment is dampened by the bearish signals from the Bollinger Bands on the weekly chart and the mildly bearish OBV on the weekly chart. The RSI shows no signals on both weekly and monthly time frames, indicating a lack of momentum. Overall, the combination of these indicators suggests a cautious outlook for RPG LifeScience in the near term.

When is the next results date for RPG Life Sciences Ltd?

The next results date for RPG Life Sciences Ltd is January 27, 2026.

The next results date for RPG Life Sciences Ltd is scheduled for January 27, 2026.

Are RPG Life Sciences Ltd latest results good or bad?

RPG Life Sciences Ltd's latest Q3 FY26 results are concerning, showing a 39.95% decline in net profit to ₹22.13 crores and a drop in profit margin from 20.28% to 12.29%. Overall, the performance indicates significant operational challenges and a bearish trend in the stock.

RPG Life Sciences Ltd's latest results for Q3 FY26 indicate a concerning performance. The company reported a net profit of ₹22.13 crores, which reflects a significant decline of 39.95% compared to the previous quarter. Additionally, net sales were ₹180.03 crores, showing a slight decrease of 0.91% from the prior quarter. <BR><BR>The profit after tax (PAT) margin has also seen a substantial drop, falling to 12.29%, down from 20.28% in Q2 FY26, which raises alarms about the company's operational efficiency. While the operating margin improved marginally to 22.09%, the overall picture is overshadowed by the sharp decline in net profit and gross profit margin, which decreased dramatically from 30.09% to 19.16%.<BR><BR>Furthermore, the stock has been under pressure, declining over 6% in the past week and more than 11% in the last month, indicating a bearish trend. The recent performance suggests that the company is facing significant operational challenges, and the shift in financial trend from "Positive" to "Flat" further emphasizes the need for close scrutiny by investors.<BR><BR>Overall, the results can be characterized as bad, reflecting serious concerns about profitability and operational sustainability moving forward.

Should I buy, sell or hold RPG Life Sciences Ltd?

Why is RPG Life Sciences Ltd falling/rising?

As of 03-Apr, RPG Life Sciences Ltd's stock price is rising to Rs 1,927.20, up 2.58%, driven by strong trading activity and outperformance against its sector. Despite concerns about long-term growth, the stock shows resilience in a bearish market, supported by solid financial health and recent profit increases.

As of 03-Apr, RPG Life Sciences Ltd's stock price is rising, currently at Rs 1,927.20, reflecting an increase of Rs 48.45 or 2.58%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 3.41% today and has shown consecutive gains over the last two days, accumulating a total return of 4.16% during this period. Additionally, the stock reached an intraday high of Rs 1,927.20, indicating strong trading activity.<BR><BR>In terms of performance relative to broader market benchmarks, RPG Life Sciences Ltd has demonstrated resilience over the past week and month, with returns of +0.87% and +5.87%, respectively, while the Sensex has declined by -2.60% and -8.62% during the same periods. This suggests that the stock is gaining traction despite a generally bearish market environment.<BR><BR>Moreover, the company maintains a low debt-to-equity ratio and has reported a 21.1% increase in profits over the past year, which, despite the stock's overall negative return of -17.61% in that timeframe, indicates a fair valuation with a PEG ratio of 1.4. This financial health may contribute to investor confidence, supporting the stock's rise.<BR><BR>However, it is important to note that there are concerns regarding long-term growth, as evidenced by the company's lower performance metrics in terms of net sales and operating profit growth over the last five years. Additionally, a significant drop in delivery volume suggests a decrease in investor participation, which could impact future price movements. Nonetheless, the current upward trend in stock price reflects a positive short-term sentiment among investors.

Why is RPG Life Sciences Ltd falling/rising?

As of 04-Apr, RPG Life Sciences Ltd's stock price is rising to 1,927.20, reflecting a 2.58% increase. This short-term gain is notable despite the stock's long-term decline, as it has outperformed its sector recently and shows positive fundamentals.

As of 04-Apr, RPG Life Sciences Ltd's stock price is rising, currently at 1,927.20, reflecting a change of 48.45 (2.58%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 3.41% today and has shown a consecutive gain over the last two days, with a total return of 4.16% during this period. Additionally, the stock reached an intraday high of Rs 1,927.20, indicating strong performance within the trading day.<BR><BR>In terms of comparative performance, RPG Life Sciences Ltd has demonstrated resilience in the short term, with a weekly return of +0.87%, while the benchmark Sensex has declined by -2.60%. Over the past month, the stock has also performed well, gaining +5.87% compared to the Sensex's -8.62%. However, it is important to note that the stock has faced challenges in the longer term, with a year-to-date decline of -16.95% and a one-year return of -17.61%, which is significantly worse than the market's overall performance.<BR><BR>Despite these long-term challenges, the company's fundamentals show some positive aspects, such as a low Debt to Equity ratio and a return on equity (ROE) of 19, suggesting fair valuation. Moreover, while the stock is trading at a premium compared to its peers, its profits have increased by 21.1% over the past year, which may contribute to investor confidence in the stock's potential for recovery.<BR><BR>In summary, the recent rise in RPG Life Sciences Ltd's stock price can be attributed to short-term gains and positive performance relative to the sector, despite ongoing long-term challenges.

Why is RPG Life Sciences Ltd falling/rising?

As of 05-Apr, RPG Life Sciences Ltd's stock price has risen to Rs 1,927.20, up 2.58%, driven by recent gains and improved profitability despite a year-to-date decline of 16.95%. The stock's fair valuation and low debt levels are positive, but it has underperformed the broader market and has limited mutual fund interest, indicating potential long-term challenges.

As of 05-Apr, RPG Life Sciences Ltd is experiencing a rise in its stock price, currently at Rs 1,927.20, reflecting an increase of 48.45 points or 2.58%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector today by 3.41% and has shown a consecutive gain over the last two days, accumulating a total return of 4.16% during this period. Additionally, the stock reached an intraday high of Rs 1,927.20, indicating positive trading momentum.<BR><BR>Despite a year-to-date decline of 16.95% and a one-year drop of 17.61%, the company has reported a profit increase of 21.1%, which suggests that while the stock price has fallen, the underlying profitability is improving. The stock's PEG ratio of 1.4 indicates a fair valuation relative to its earnings growth, and it has a low Debt to Equity ratio, which is a positive indicator for investors.<BR><BR>However, it is important to note that while the stock is rising currently, it has underperformed the broader market over the past year, and domestic mutual funds hold a minimal stake in the company, which may reflect a lack of confidence in its long-term growth prospects. Overall, the recent price increase can be seen as a response to short-term trading dynamics and improving profitability, despite the longer-term challenges the company faces.

Which are the latest news on RPG LifeScience.?

Which are the latest news on RPG LifeScience.?

Which are the latest news on RPG LifeScience.?